Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

BACKGROUND: Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can limit drug exposure, which may impact on extracr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S. W., Lim, Darren Wan-Teck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276185/
https://www.ncbi.nlm.nih.gov/pubmed/30509246
http://dx.doi.org/10.1186/s12885-018-5110-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276185/
https://www.ncbi.nlm.nih.gov/pubmed/30509246
http://dx.doi.org/10.1186/s12885-018-5110-2

Ejemplares similares